Article Contents
- 2023 (Vol.86)
- 2022 (Vol.85)
- 2021 (Vol.84)
- 2020 (Vol.83)
- 2019 (Vol.82)
- 2018 (Vol.81)
- 2017 (Vol.80)
- 2016 (Vol.79)
- 2015 (Vol.78)
- 2014 (Vol.76)
- 2013 (Vol.74)
- 2012 (Vol.72)
- 2011 (Vol.70)
- 2010 (Vol.68)
- 2009 (Vol.66)
- 2008 (Vol.64)
- 2007 (Vol.62)
- 2006 (Vol.60)
- 2005 (Vol.58)
- 2004 (Vol.56)
- 2003 (Vol.54)
- 2002 (Vol.52)
Phase Ⅱ Study of Gemcitabine and Vinorelbine as a Combination Chemotherapy for the Second-Line Treatment of Nonsmall Cell Lung Carcinoma
- Downloaded
- Viewed
Abstract
Backgroud : Lung cancer is the leading cause of cancer deaths in Korea and the number of lung cancer deaths is increasing. The higher response rates, decreased toxicity and improved performance status of the first-line treatments have resulted in an increased number of patients becoming candidates for second-line therapy. Several new antineoplastic agents, including gemcitabine, docetaxel and paclitaxel, have recently demonstrated second-line activity. This phase II study evaluated the efficacy and toxicity of gemcitabine and vinorelbine as combination chemotherapy for Korean patients with NSCLC as a second-line treatment. Methods : Sixty response-evaluable patients were enrolled from December 2000 to July 2003. We conducted a phase II study of a combination gemcitabine and vinorelbine chemotherapy for patients with histologically confirmed NSCLC that was stage IIIB and IV disease at the time of diagnosis, and the disease had progressed onward or the patients had relapsed after first-line platinum-based chemotherapy. They were treated with intravenous gemcitabine 1000mg/m2 and intravenous vinorelbine 25mg/m2 on days 1 and 8. This chemotherapy regimen was repeated every 3 weeks. Results : A total of 215 cycles of treatment were given and the mean number of cycles was 3.6 cycles. All the patients were evaluable for the toxicity profile. The response rate was 10% according to the WHO criteria. The median progression free survival was 3.8 months and the median survival time was 10.1 months. The 1-year survival rate was 32.9%. Grade III and IV neutropenia were seen in 20 (33.3%) and 7 (11.7%) patients, respectively. Conclusion : The combination of gemcitabine and vinorelbine is active and well tolerated as a second-line therapy for patients with advanced nonsmall cell lung carcinoma. (Tuberc Respir Dis 2005; 59: 510-516)
- keywords
- Nonsmall cell lung cancer, Gemcitabine, Vinorelbine, Phase II study, Nonsmall cell lung cancer, Gemcitabine, Vinorelbine, Phase II study
Reference
(2004) The result of cause of death in 2003, Korea National Statistical office
(2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer,
(2004) Second-line chemotherapy for non-small- cell lung cancer:recent data with pemetrexed,
(2004) Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer,
(2004) Second-line chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC),
(2005) The current situation:erlotinib and gefitinib in non-small cell lung cancer,
(1996) Vinorebine:an overview,
(1991) A phase II study of vinorelbine in the treatment of non-small cell lung cancer,
(1994) A phase II study of vinorelbine,a new derivative of vinca alkaloid,for previously untrated advanced non-small cell lung cancer,
(1997) Modified weekly regimen with vinorelbine as a single agent in unresectable non- small cell lung cancer,
(2002) The novel and effective nonplatinum,nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma,
(2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non- small cell lung cancer,
(1994) Efficacy and safety profile of gemcitabine in non-small cell lung cancer:a phase II study,
(1997) Cisplatin-gemcitabine combination in advanced non-small cell lung cance:a phase II study,
(2001) Gemcitabine and vinorelbine as first-line therapy for non-small cell lung cancer:a phase II trial,
(1995) Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer:an overview,
(1997) Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer:a two stage phage II study,
(2000) Gemcitabine and vinorelbine in the second-line treatment of non-small cell lung carcinomas patients,
(2000) Second-line treatment with gemcitabine and vinorelbine in non-small cell lung cancer cisplatin failures: a pilot study.,
(2001) Gemcitabine and vinorelbine as second-line therapy in non-small cell lung cancer after prior treatment with taxene+platinum-based regimens,
(2001) An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy:a phase II study of the Hellenic co-operative oncology group,
(2005) Gemcitabine plus vinorelbine as second-line chemotherapy of the patients of previously treated non-small cell lung cancer,
(2004) Gemcitabine and vinorelbine as second-line therapy for non- small cell lung cancer after treatment with paclitaxel plus platinum,
(2001) Comparision of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer:early results of a randomized trial,
(2001) Challenging the platinum combinations:docetaxel combined with gemcitabine or vinorelbine in non-small cell lung caner,
(2000) Interim results of a Phase III trial.Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non-small cell lung cancer,
- Downloaded
- Viewed
- 0KCI Citations
- 0WOS Citations